Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients
Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients Moneycontrol Latest News Read More